Navigation Links
PharmaDirections Announces Appointment of Dr. Bruce Rehlaender as Principal, Formulation Development
Date:1/22/2013

Cary, NC (PRWEB) January 22, 2013

Dr. Bruce Rehlaender has been appointed a Principal, Formulation Development at PharmaDirections. He will be based in the Portland, Oregon area and will have proximity to a growing market in early stage drug development. The appointment is a reflection of the invaluable contributions he has made over the past 6 years to the virtual biotech companies served by PharmaDirections.

Dr. Rehlaender joined PharmaDirections in 2007 as the Director, Formulation Development. In that capacity, he led multi-disciplinary teams of product development scientists who developed novel drug products using specialized expertise in biopharmaceutics, pharmacokinetics and formulation development.

There have been many significant achievements in his tenure, but we only have room for a few. Dr. Rehlaender led the development of the tri-layer, sustained release tablet formulations for Orexigen’s Contrave; that NDA was filed in 2010. He led many In-Silico PK Modeling programs that resulted in establishing optimum release patterns for over 12 unique client programs. He is the inventor on 5 patents that were developed for PharmaDirections’ clients was responsible for the formulation development efforts in over 20 unique client programs.

Over his 25 year industrial career, Dr. Rehlaender has developed his expertise in biopharmaceutics and formulation development with special expertise in challenges such as poorly soluble drugs, unstable compounds, and sophisticated controlled release patterns. He has extensive experience in developing parenteral products; oral tablets, capsules, and liquids; nebulizer products; dry powder inhalers; and topicals. His experience covers product processing from bench top to commercial manufacturing where he has developed processes for emulsification, powder milling, steam sterilization; aseptic manufacture; lyophilization; and separation of proteins.

Dr. Rehlaender's analytical expertise is primarily in solids characterization, including differential scanning calorimetry, thermogravimetric analysis, dynamic vapor sorption, powder flow measurement, and particle sizing using laser diffraction, photon correlation spectroscopy; electrozone sensing, and light obscuration.

About PharmaDirections

PharmaDirections is a consulting and project management company with a unique approach to managing preclinical, CMC and regulatory affairs programs. We provide strategic planning then oversee and direct pharmaceutical contract research using our own scientific experts and project managers. We are a comprehensive resource for virtual pharmaceutical and biotech companies who need to stay lean by outsourcing their R&D activities.

http://www.PharmaDirections.com

Read the full story at http://www.prweb.com/releases/2013/1/prweb10341546.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. PharmaDirections Succeeds Through its Client’s Successes: Cortendo Receives Positive Orphan Drug Opinion from EMA for NormoCort for Cushing’s Disease
2. NSG Announces New Quartz Micro Flow Channel
3. Amgen Announces Webcast of 2012 Fourth Quarter and Full Year Financial Results
4. Inflamax Research announces the launch of its Mobile Environmental Exposure Chamber™ for conduct of Allergy & Asthma Trials
5. ASAE Foundation Announces Winners of the Innovation Grant Program
6. LATISTA Announces Next-Generation iPad App 2.0 for Construction with Industry Leading Innovations
7. GlycoCheck Announces Partnership in the United States with Vascular Health Sciences
8. Wysebridge Patent Bar Review Announces the Launch of News Blog
9. Convoy Therapeutics Announces the Relaunch of Their Interactive Website
10. BroadData Conferencing Announces Enhanced International Audio Conference Call Capabilities
11. MakeSigns.com Announces New Tri-Fold Scientific Poster Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , ... April 29, 2016 , ... ... personalized pain medicine, is excited to announce the launch of the Proove ... health studies, volunteerism, and education to promote the use of personalized medicine for ...
(Date:4/29/2016)... , April 29, 2016 ... by Transparency Market Research "Separation Systems for Commercial ... Growth, Trends, and Forecast 2015 - 2023", the ... at US$ 10,665.5 Mn in 2014 and is ... from 2015 to 2023 to reach US$ 19,227.8 ...
(Date:4/29/2016)... ... April 29, 2016 , ... Summit for Stem Cell has received a ... a patient-specific stem cell therapy for the treatment of Parkinson’s disease. The Summit research ... at The Scripps Research Institute in San Diego, CA. , The aim ...
(Date:4/29/2016)... 2016 Elekta is pleased to ... its industry-leading treatment planning software, is available for clinical ... version 5.11 provides significant performance speed enhancements ... up to four times faster than in previous versions ... gold standard Monte Carlo algorithm, ...
Breaking Biology Technology:
(Date:3/14/2016)... March 14, 2016 NXTD ) ("NXT-ID" ... commerce market, announces the airing of a new series of ... week of March 21 st .  The commercials will air ... popular Squawk on the Street show. --> NXTD ... growing mobile commerce market, announces the airing of a new ...
(Date:3/10/2016)... 2016   Unisys Corporation (NYSE: UIS ) ... (CBP) is testing its biometric identity solution at the Otay ... to help identify certain non-U.S. citizens leaving the country. ... to help determine the efficiency and accuracy of using biometric ... will run until May 2016. --> the ...
(Date:3/3/2016)... 2016  FlexTech, a SEMI Strategic Association Partner, awarded ... & Development, Leadership in Education, and, in a category ... th year of the FLEXI Awards and the ... from past years . Judging was done on ... of criteria, by a panel of non-affiliated, independent, industry ...
Breaking Biology News(10 mins):